Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial

Dimopoulos, Meletios A.; Dytfeld, Dominik; Grosicki, Sebastian; Moreau, Philippe; Takezako, Naoki; Hori, Mitsuo; Leleu, Xavier; LeBlanc, Richard; Suzuki, Kenshi; Raab, Marc S.; Richardson, Paul G.; Popa McKiver, Mihaela; Jou, Ying-Ming; Yao, David; Das, Prianka; San-Miguel, Jesús

doi:10.1200/jco.21.02815

Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial

PURPOSE In the phase II ELOQUENT-3 trial (ClinicalTrials.gov identifier: NCT02654132 ), elotuzumab combined with pomalidomide/dexamethasone (EPd) significantly improved progression-free survival (PFS) versus pomalidomide/dexamethasone (Pd) in patients with relapsed/refractory multiple myeloma (RR…